ParaguayTuberculosis profile
Population  2015 6.6 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.26 (0.22–0.31) 4 (3.3–4.7)
Mortality (HIV+TB only) 0.035 (<0.01–0.11) 0.53 (0.03–1.7)
Incidence  (includes HIV+TB) 2.7 (2.3–3.1) 41 (35–47)
Incidence (HIV+TB only) 0.24 (0.2–0.28) 3.6 (3–4.2)
Incidence (MDR/RR-TB)** 0.087 (0.044–0.13) 1.3 (0.66–2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.15 (0.095–0.2) 0.71 (0.4–1) 0.86 (0.5–1.2)
Males 0.15 (0.1–0.19) 1.7 (1.3–2.1) 1.9 (1.4–2.3)
Total 0.3 (0.23–0.36) 2.4 (2.2–2.6) 2.7 (2.3–3.1)
TB case notifications, 2015  
Total cases notified 2 536
Total new and relapse 2 358
          - % tested with rapid diagnostics at time of diagnosis 14%
          - % with known HIV status 86%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.08–0.15)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 178 9%
          - on antiretroviral therapy 150 84%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  76
(26–130)
Estimated % of TB cases with MDR/RR-TB 0.9% (0–2.2) 15% (4–25)  
% notified tested for rifampicin resistance 26% 49% 758
MDR/RR-TB cases tested for resistance to second-line drugs   3
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 71% 2 240
Previously treated cases, excluding relapse, registered in 2014 51% 164
HIV-positive TB cases, all types, registered in 2014 39% 179
MDR/RR-TB cases started on second-line treatment in 2013 33% 6
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 7%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
30% (27–33)
TB financing, 2016  
National TB budget (US$ millions) 24
Funding source: 15% domestic, 9% international, 77% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data